Healthcare Sales & Marketing Network News: Veloxis Pharmaceuticals

Searching News Database: Veloxis Pharmaceuticals

HSMN NewsFeed - 20 Apr 2018
FDA Accepts Veloxis's Supplemental New Drug Application for the De Novo Indication for ENVARSUS XR(R)
Biopharmaceuticals FDA

HSMN NewsFeed - 27 Mar 2017
Bridge Medicines Appoints William J. Polvino, M.D., As Chief Executive Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 21 Jun 2016
Keryx Biopharmaceuticals Appoints Two New Board Members
Biopharmaceuticals Personnel

HSMN NewsFeed - 31 Oct 2014
Veloxis announces tentative approval of Envarsus(R) XR
Biopharmaceuticals FDA

HSMN NewsFeed - 22 May 2014
Veloxis Receives Positive Opinion from CHMP for Envarsus(R) for Treatment of Both Kidney and Liver Transplant Patients
Biopharmaceuticals Regulatory

HSMN NewsFeed - 24 Dec 2013
Veloxis Pharmaceuticals Envarsus(R) Granted Orphan Drug Status by U.S. Food and Drug Administration for Kidney Transplant Rejection Prophylaxis
Biopharmacecuticals FDA

HSMN NewsFeed - 23 May 2012
Veloxis Pharmaceuticals announces a restructuring of the company to support and strengthen strategic focus on LCP-Tacro(TM) and announces changes to management
Biopharmaceuticals Personnel

Return to NewsFeed

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.

FindReps - available on the Apple App Store for iPhone and iPad.